Eugene Schneider - 18 Jan 2022 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role: EVP, Chf Clinical Develop Offc
Signature: By: Patrick R. O'Neil, attorney-in-fact For: Eugene Schneider
Issuer symbol: IONS
Transactions as of: 18 Jan 2022
Net transactions value: -$114,908
Form type: 4
Filing time: 20 Jan 2022, 19:16:14 UTC
Previous filing: 19 Jan 2022
Next filing: 18 Oct 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IONS	Common Stock	Options Exercise	$0	+10,400	+145%	$0.000000	17,575	18 Jan 2022	Direct	F1
transaction	IONS	Common Stock	Tax liability	$114,908	-3,815	-22%	$30.12	13,760	18 Jan 2022	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IONS	Restricted Stock Unit	Options Exercise	$0	-10,400	-22%	$0.000000	36,325	18 Jan 2022	Common Stock	10,400	$0.000000	Direct	F3, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.
F2	Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
F3	Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
F4	Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.